| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733772 | Critical Reviews in Oncology/Hematology | 2017 | 36 Pages |
Abstract
In clinical practice opioids remain the most important pharmacologic treatment for severe pain related to bone cancer. Regard developing drugs, anti-NGF and anti-TrkA are the most investigated new drug in this setting, but a future role in clinical practice is still uncertain.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Maurizio Lucchesi, Gaetano Lanzetta, Andrea Antonuzzo, Antonio Rozzi, Iacopo Sardi, Claudio Favre, Carla Ida Ripamonti, Daniele Santini, Grazia Armento,